Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (26): 4791-4795.doi: 10.3969/j.issn.1673-8225.2010.26.010

Previous Articles     Next Articles

Zoledronic acid and pamidronate disodium for treating malignant bone metastasis pain: A Meta-analysis of effectiveness and safety

Wang Kai1, Wang Shuan-ke1, Zhao Bin1, Wang Na2   

  1. 1Department of Orthopedics, Second Hospital of Lanzhou University, Lanzhou  730000, Gansu Province, China;
    2Department of Oncological Surgery, First Hospital of Lanzhou University, Lanzhou  730000, Gansu Province, China
  • Online:2010-06-25 Published:2010-06-25
  • Contact: Wang Shuan-ke, Doctor, Doctoral supervisor, Department of Orthopedics, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China wskzzzy@yahoo．com.cn
  • About author:Wang Kai, Studying for master’s degree, Physician, Department of Orthopedics, Second Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China 56966186@qq.com

PDF

663

Abstract:

BACKGROUND: Bone metastasis is a major reason for tumorous pain. The third generation of diphosphonate zoledronic acid and the second generation of pamidronate disodium display several clinical features in treating pain caused by bone metastasis, such as short administration, low dose and long effect.

OBJECTIVE: To assess the effectiveness and safety of zoledronic acid compared with pamidronate disodium in treatment of pain caused by bone metastasis of malignance neoplasms.

METHODS: A computer-based online search of Cochrane library, PubMed, EMBase, Chinese Biomedical Literature Database, China Journal Full-text Database, and Chinese Scientific Journal Full-text Database was performed. Randomized controlled trails (RCTs) on zoledronic acid and pamidronate in treatment of pain caused by bone metastasis of malignance neoplasms were identified. The methodological quality of the included studies was evaluated, and data analyses were performed using RevMan 5.0 software.

RESULTS AND CONCLUSION: A total of 10 randomized controlled trials involving 2 731 patients were studied. Of the 10 trials, 7 were performed in China, and 3 in the United States. Evaluation of the methodological quality showed that the 10 RCTs had a moderate risk of bias. The result of Meta-analysis showed that there was no significant difference in the complete response rate (CR rate), partial response rate or total effective rate, (RR = 1.59, 95% CI: 0.91-2.80) (RR = 0.95, 95% CI: 0.81-1.12) (RR = 1.04, 95% CI: 0.97-1.12). Significant difference was noted in side effects but headache (RR = 0.82, 95% CI: 0.70-0.96). As to response rate and side effect, zoledronic acid was similar to pamidronate.

CLC Number: